Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Lymphoid 1Head & Neck 1Gynecologic 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Sarcoma 5Histiocytoma, Malignant Fibrous 4Gastrointestinal Stromal Tumors 4Osteosarcoma 2Neoplasm Metastasis 2Melanoma 2Liposarcoma 2Gliosarcoma 2Bone Neoplasms 2Vulvar Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Somatostatinoma 1Seminoma 1Sarcoma, Kaposi 1Rhabdomyosarcoma 1Rare Diseases 1Pseudomyxoma Peritonei 1Pheochromocytoma 1Perivascular Epithelioid Cell Neoplasms 1Parathyroid Neoplasms 1Paranasal Sinus Neoplasms 1Paraganglioma 1Paget Disease, Extramammary 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Nasopharyngeal Carcinoma 1

Interventions

Ifosfamide 30Methotrexate 29Doxorubicin 26Cyclophosphamide 24Cisplatin 22Filgrastim 18Etoposide 17Gemcitabine 16Leucovorin 14Magnetic Resonance Spectroscopy 11Temozolomide 10Specimen Handling 10cabozantinib 9apatinib 9X-Rays 9Carboplatin 9fludarabine 8Radiotherapy 8Nivolumab 8Neoadjuvant Therapy 8Irinotecan 8Granulocyte Colony-Stimulating Factor 8Drug Therapy 8Docetaxel 8Zoledronic Acid 7Vincristine 7Sirolimus 7Phantoms, Imaging 7Biopsy 7mifamurtide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Osteosarcoma × CTLA-4 Antigen × Sarcoma × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT02304458 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

National Cancer Institute (NCI)

Phase 1/2 Completed
140 enrolled 23 charts
CNSDermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡